1uts

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
(New page: 200px<br /> <applet load="1uts" size="450" color="white" frame="true" align="right" spinBox="true" caption="1uts" /> '''DESIGNED HIV-1 TAR BINDING LIGAND'''<br /> ...)
Line 1: Line 1:
-
[[Image:1uts.gif|left|200px]]<br />
+
[[Image:1uts.gif|left|200px]]<br /><applet load="1uts" size="350" color="white" frame="true" align="right" spinBox="true"
-
<applet load="1uts" size="450" color="white" frame="true" align="right" spinBox="true"
+
caption="1uts" />
caption="1uts" />
'''DESIGNED HIV-1 TAR BINDING LIGAND'''<br />
'''DESIGNED HIV-1 TAR BINDING LIGAND'''<br />
==Overview==
==Overview==
-
The targeting of RNA for the design of novel anti-viral compounds, represents an area of vast potential. We have used NMR and computational, methods to model the interaction of a series of synthetic inhibitors of, the in vitro RNA binding activities of a peptide derived from the, transcriptional activator protein, Tat, from human immunodeficiency virus, type 1. Inhibition has been measured through the monitering of, fluorescence resonance energy transfer between fluorescently labeled, peptide and RNA components. A series of compounds containing a bi-aryl, heterocycle as one of the three substituents on a benzylic scaffold, induce a novel, inactive TAR conformation by stacking between base-pairs, at the site of a three-base bulge within TAR. The development of this, series resulted in an enhancement in potency (with Ki &lt; 100 nM in an in, vitro assay) and the removal of problematic guanidinium moieties. Ligands, from this series can act as inhibitors of Tat-induced transcription in a, cell-free system. This study validates the drug design strategy of using a, ligand to target the RNA receptor in a non-functional conformation.
+
The targeting of RNA for the design of novel anti-viral compounds represents an area of vast potential. We have used NMR and computational methods to model the interaction of a series of synthetic inhibitors of the in vitro RNA binding activities of a peptide derived from the transcriptional activator protein, Tat, from human immunodeficiency virus type 1. Inhibition has been measured through the monitering of fluorescence resonance energy transfer between fluorescently labeled peptide and RNA components. A series of compounds containing a bi-aryl heterocycle as one of the three substituents on a benzylic scaffold, induce a novel, inactive TAR conformation by stacking between base-pairs at the site of a three-base bulge within TAR. The development of this series resulted in an enhancement in potency (with Ki &lt; 100 nM in an in vitro assay) and the removal of problematic guanidinium moieties. Ligands from this series can act as inhibitors of Tat-induced transcription in a cell-free system. This study validates the drug design strategy of using a ligand to target the RNA receptor in a non-functional conformation.
==About this Structure==
==About this Structure==
-
1UTS is a [http://en.wikipedia.org/wiki/Single_protein Single protein] structure of sequence from [http://en.wikipedia.org/wiki/ ] with P13 as [http://en.wikipedia.org/wiki/ligand ligand]. Full crystallographic information is available from [http://ispc.weizmann.ac.il/oca-bin/ocashort?id=1UTS OCA].
+
1UTS is a [http://en.wikipedia.org/wiki/Single_protein Single protein] structure of sequence from [http://en.wikipedia.org/wiki/ ] with <scene name='pdbligand=P13:'>P13</scene> as [http://en.wikipedia.org/wiki/ligand ligand]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=1UTS OCA].
==Reference==
==Reference==
Line 16: Line 15:
[[Category: Davis, B.]]
[[Category: Davis, B.]]
[[Category: Karn, J.]]
[[Category: Karn, J.]]
-
[[Category: Murchie, A.I.H.]]
+
[[Category: Murchie, A I.H.]]
[[Category: P13]]
[[Category: P13]]
[[Category: antiviral]]
[[Category: antiviral]]
Line 25: Line 24:
[[Category: tar rna]]
[[Category: tar rna]]
-
''Page seeded by [http://ispc.weizmann.ac.il/oca OCA ] on Thu Nov 8 14:33:34 2007''
+
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Thu Feb 21 15:28:14 2008''

Revision as of 13:28, 21 February 2008


1uts

Drag the structure with the mouse to rotate

DESIGNED HIV-1 TAR BINDING LIGAND

Overview

The targeting of RNA for the design of novel anti-viral compounds represents an area of vast potential. We have used NMR and computational methods to model the interaction of a series of synthetic inhibitors of the in vitro RNA binding activities of a peptide derived from the transcriptional activator protein, Tat, from human immunodeficiency virus type 1. Inhibition has been measured through the monitering of fluorescence resonance energy transfer between fluorescently labeled peptide and RNA components. A series of compounds containing a bi-aryl heterocycle as one of the three substituents on a benzylic scaffold, induce a novel, inactive TAR conformation by stacking between base-pairs at the site of a three-base bulge within TAR. The development of this series resulted in an enhancement in potency (with Ki < 100 nM in an in vitro assay) and the removal of problematic guanidinium moieties. Ligands from this series can act as inhibitors of Tat-induced transcription in a cell-free system. This study validates the drug design strategy of using a ligand to target the RNA receptor in a non-functional conformation.

About this Structure

1UTS is a Single protein structure of sequence from [1] with as ligand. Full crystallographic information is available from OCA.

Reference

Structure-based drug design targeting an inactive RNA conformation: exploiting the flexibility of HIV-1 TAR RNA., Murchie AI, Davis B, Isel C, Afshar M, Drysdale MJ, Bower J, Potter AJ, Starkey ID, Swarbrick TM, Mirza S, Prescott CD, Vaglio P, Aboul-ela F, Karn J, J Mol Biol. 2004 Feb 20;336(3):625-38. PMID:15095977

Page seeded by OCA on Thu Feb 21 15:28:14 2008

Proteopedia Page Contributors and Editors (what is this?)

OCA

Personal tools